Market Cap 12.77B
Revenue (ttm) 13.64B
Net Income (ttm) 746.80M
EPS (ttm) N/A
PE Ratio 16.94
Forward PE 13.18
Profit Margin 5.47%
Debt to Equity Ratio -22.49
Volume 586,295
Avg Vol 879,160
Day's Range N/A - N/A
Shares Out 64.20M
Stochastic %K 96%
Beta 0.84
Analysts Sell
Price Target $190.50

Company Profile

DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administ...

Industry: Medical Care Facilities
Sector: Healthcare
Phone: 720 631 2100
Address:
2000 16th Street, Denver, United States
MegansKEY
MegansKEY Jun. 3 at 11:24 PM
0 · Reply
Noname2022
Noname2022 Jun. 3 at 10:34 PM
$CRMD $AKBA $FMS $DVA Re: K-CAPA & June/July CMS update
0 · Reply
Noname2022
Noname2022 Jun. 3 at 3:27 PM
2 · Reply
Noname2022
Noname2022 May. 28 at 9:38 PM
$AKBA $DVA Something potentially positive from Davita for an AKBA investor (which I’m not…) “Over the coming five years, we commit to reducing the average hospitalization rate among the patients we serve, as measured against a 2025 baseline.” https://davita.com/communitycare/patients/
0 · Reply
TradeTracs
TradeTracs May. 28 at 4:53 AM
$DVA such an impressive chart TA setup since our last call on it, now setting up another post earnings gap flag, potential inside day against 10ema daily
0 · Reply
REZZAYO
REZZAYO May. 27 at 6:01 PM
$CRMD Judging by the Stock Activity, $DVA already Signed, pending Announcement only, likely will be on Quarter Beginning July 1st ~ 18K Patients, Probably will Start with 6-8K then Ramping Up similar to $FMS
1 · Reply
Noname2022
Noname2022 May. 27 at 3:37 AM
$CRMD $DVA $FMS $AKBA June / July ESRD update still on track!
1 · Reply
Noname2022
Noname2022 May. 27 at 2:53 AM
$CRMD $DVA “Broadly, two most common causes of hospitalization in people with kidney failure are cardiovascular disease and infection” https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/5-hospitalization?utm_source=chatgpt.com
0 · Reply
Noname2022
Noname2022 May. 27 at 2:36 AM
1 · Reply
Noname2022
Noname2022 May. 26 at 8:38 PM
$CRMD $DVA $FMS Medicare Advantage update: tri-party discussions https://stockanalysis.com/stocks/crmd/transcripts/673503-rbc-capital-markets-global-healthcare-conference-2026/
0 · Reply
Latest News on DVA
DaVita price target raised to $201 from $144 at TD Cowen

2026-05-11T14:28:21.000Z - 23 days ago

DaVita price target raised to $201 from $144 at TD Cowen


DaVita price target raised to $205 from $158 at Truist

2026-05-08T11:57:34.000Z - 26 days ago

DaVita price target raised to $205 from $158 at Truist


DaVita price target raised to $235 from $190 at UBS

2026-05-07T13:29:05.000Z - 27 days ago

DaVita price target raised to $235 from $190 at UBS


DaVita price target raised to $194 from $158 at Barclays

2026-05-07T11:44:30.000Z - 27 days ago

DaVita price target raised to $194 from $158 at Barclays


DaVita upgraded to Buy from Hold at Deutsche Bank

2026-05-07T10:41:29.000Z - 27 days ago

DaVita upgraded to Buy from Hold at Deutsche Bank


DaVita rises 19.6%

2026-05-07T03:38:03.000Z - 4 weeks ago

DaVita rises 19.6%


DaVita Earnings Call Transcript: Q1 2026

May 5, 2026, 5:00 PM EDT - 4 weeks ago

DaVita Earnings Call Transcript: Q1 2026


DaVita Earnings release: Q1 2026

May 5, 2026, 5:00 PM EDT - 4 weeks ago

DaVita Earnings release: Q1 2026


DaVita Quarterly report: Q1 2026

May 5, 2026, 5:00 PM EDT - 4 weeks ago

DaVita Quarterly report: Q1 2026


DaVita reports Q1 EPS $2.87, consensus $2.33

2026-05-05T20:28:38.000Z - 4 weeks ago

DaVita reports Q1 EPS $2.87, consensus $2.33


DaVita sees FY26 adjusted EPS $14.10-$15.20, consensus $14.12

2026-05-05T20:23:26.000Z - 4 weeks ago

DaVita sees FY26 adjusted EPS $14.10-$15.20, consensus $14.12


DaVita Inc. 1st Quarter 2026 Results

May 5, 2026, 4:05 PM EDT - 4 weeks ago

DaVita Inc. 1st Quarter 2026 Results


DaVita Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

DaVita Proxy statement: Proxy filing


DaVita Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 6 weeks ago

DaVita Proxy statement: Proxy filing


DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call

Apr 20, 2026, 2:06 PM EDT - 6 weeks ago

DaVita Inc. Schedules 1st Quarter 2026 Investor Conference Call


DaVita Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 11:50 AM EST - 3 months ago

DaVita Transcript: TD Cowen 46th Annual Health Care Conference


DaVita price target raised to $158 from $128 at Truist

2026-02-05T15:05:21.000Z - 4 months ago

DaVita price target raised to $158 from $128 at Truist


DaVita price target raised to $144 from $133 at TD Cowen

2026-02-04T13:50:41.000Z - 4 months ago

DaVita price target raised to $144 from $133 at TD Cowen


DaVita price target raised to $190 from $186 at UBS

2026-02-04T11:36:08.000Z - 4 months ago

DaVita price target raised to $190 from $186 at UBS


DaVita rises 21.7%

2026-02-03T17:05:35.000Z - 4 months ago

DaVita rises 21.7%


TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings

Feb 3, 2026, 11:00 AM EST - 4 months ago

TER Quarterly Sales Top $1B, DVA & PEP Beat Earnings

PEP TER


DaVita Earnings Call Transcript: Q4 2025

Feb 2, 2026, 5:00 PM EST - 4 months ago

DaVita Earnings Call Transcript: Q4 2025


DaVita Annual report: Q4 2025

Feb 2, 2026, 5:00 PM EST - 4 months ago

DaVita Annual report: Q4 2025


DaVita Earnings release: Q4 2025

Feb 2, 2026, 5:00 PM EST - 4 months ago

DaVita Earnings release: Q4 2025


DaVita Annual report: Q4 2025

Feb 2, 2026, 5:00 PM EST - 4 months ago

DaVita Annual report: Q4 2025


DaVita Inc. 4th Quarter 2025 Results

Feb 2, 2026, 4:05 PM EST - 4 months ago

DaVita Inc. 4th Quarter 2025 Results


DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call

Jan 21, 2026, 10:00 AM EST - 4 months ago

DaVita Inc. Schedules 4th Quarter 2025 Investor Conference Call


DaVita Names New Leaders to Accelerate Care Transformation

Dec 11, 2025, 8:00 AM EST - 6 months ago

DaVita Names New Leaders to Accelerate Care Transformation


DaVita Transcript: Wolfe Research Healthcare Conference 2025

Nov 17, 2025, 11:20 AM EST - 7 months ago

DaVita Transcript: Wolfe Research Healthcare Conference 2025


DaVita Inc. to Participate in Fireside Chat with Wolfe Research

Nov 14, 2025, 4:16 PM EST - 7 months ago

DaVita Inc. to Participate in Fireside Chat with Wolfe Research


DaVita Earnings Call Transcript: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 7 months ago

DaVita Earnings Call Transcript: Q3 2025


DaVita Quarterly report: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 7 months ago

DaVita Quarterly report: Q3 2025


DaVita Earnings release: Q3 2025

Oct 29, 2025, 5:00 PM EDT - 7 months ago

DaVita Earnings release: Q3 2025


DaVita Inc. 3rd Quarter 2025 Results

Oct 29, 2025, 4:05 PM EDT - 7 months ago

DaVita Inc. 3rd Quarter 2025 Results


DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call

Oct 13, 2025, 2:00 PM EDT - 8 months ago

DaVita Inc. Schedules 3rd Quarter 2025 Investor Conference Call


DaVita Earnings Call Transcript: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 10 months ago

DaVita Earnings Call Transcript: Q2 2025


DaVita Quarterly report: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 10 months ago

DaVita Quarterly report: Q2 2025


DaVita Earnings release: Q2 2025

Aug 5, 2025, 5:00 PM EDT - 10 months ago

DaVita Earnings release: Q2 2025


DaVita Inc. 2nd Quarter 2025 Results

Aug 5, 2025, 4:05 PM EDT - 10 months ago

DaVita Inc. 2nd Quarter 2025 Results


DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call

Jul 17, 2025, 5:37 PM EDT - 11 months ago

DaVita Inc. Schedules 2nd Quarter 2025 Investor Conference Call


DaVita Inc. Announces Offering of $750 Million Senior Notes

May 20, 2025, 8:51 AM EDT - 1 year ago

DaVita Inc. Announces Offering of $750 Million Senior Notes


DaVita Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

DaVita Earnings Call Transcript: Q1 2025


DaVita Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

DaVita Quarterly report: Q1 2025


DaVita Earnings release: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

DaVita Earnings release: Q1 2025


DaVita First-Quarter 2025 Financial Results: Just the Numbers

May 12, 2025, 4:51 PM EDT - 1 year ago

DaVita First-Quarter 2025 Financial Results: Just the Numbers


DaVita Inc. 1st Quarter 2025 Results

May 12, 2025, 4:05 PM EDT - 1 year ago

DaVita Inc. 1st Quarter 2025 Results


DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call

Apr 30, 2025, 11:00 AM EDT - 1 year ago

DaVita Inc. Schedules 1st Quarter 2025 Investor Conference Call


DaVita Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

DaVita Proxy statement: Proxy Filing


DaVita Proxy statement: Proxy Filing

Apr 24, 2025, 8:00 AM EDT - 1 year ago

DaVita Proxy statement: Proxy Filing


DaVita Says Ransomware Attack Affecting Some Operations

Apr 14, 2025, 7:35 AM EDT - 1 year ago

DaVita Says Ransomware Attack Affecting Some Operations


Dialysis firm DaVita hit by ransomware attack

Apr 14, 2025, 7:33 AM EDT - 1 year ago

Dialysis firm DaVita hit by ransomware attack


Berkshire Hathaway sells another 750,000 DaVita shares

Feb 19, 2025, 8:05 PM EST - 1 year ago

Berkshire Hathaway sells another 750,000 DaVita shares


Berkshire sells some DaVita shares, cuts stake to 45%

Feb 13, 2025, 8:13 PM EST - 1 year ago

Berkshire sells some DaVita shares, cuts stake to 45%


DaVita forecasts 2025 profit below estimates, shares plummet

Feb 13, 2025, 6:07 PM EST - 1 year ago

DaVita forecasts 2025 profit below estimates, shares plummet


DaVita Earnings Call Transcript: Q4 2024

Feb 13, 2025, 5:00 PM EST - 1 year ago

DaVita Earnings Call Transcript: Q4 2024


DaVita Annual report: Q4 2024

Feb 13, 2025, 5:00 PM EST - 1 year ago

DaVita Annual report: Q4 2024


DaVita Earnings release: Q4 2024

Feb 13, 2025, 5:00 PM EST - 1 year ago

DaVita Earnings release: Q4 2024


DaVita Inc. 4th Quarter 2024 Results

Feb 13, 2025, 4:05 PM EST - 1 year ago

DaVita Inc. 4th Quarter 2024 Results


DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call

Jan 30, 2025, 11:55 AM EST - 1 year ago

DaVita Inc. Schedules 4th Quarter 2024 Investor Conference Call


MegansKEY
MegansKEY Jun. 3 at 11:24 PM
0 · Reply
Noname2022
Noname2022 Jun. 3 at 10:34 PM
$CRMD $AKBA $FMS $DVA Re: K-CAPA & June/July CMS update
0 · Reply
Noname2022
Noname2022 Jun. 3 at 3:27 PM
2 · Reply
Noname2022
Noname2022 May. 28 at 9:38 PM
$AKBA $DVA Something potentially positive from Davita for an AKBA investor (which I’m not…) “Over the coming five years, we commit to reducing the average hospitalization rate among the patients we serve, as measured against a 2025 baseline.” https://davita.com/communitycare/patients/
0 · Reply
TradeTracs
TradeTracs May. 28 at 4:53 AM
$DVA such an impressive chart TA setup since our last call on it, now setting up another post earnings gap flag, potential inside day against 10ema daily
0 · Reply
REZZAYO
REZZAYO May. 27 at 6:01 PM
$CRMD Judging by the Stock Activity, $DVA already Signed, pending Announcement only, likely will be on Quarter Beginning July 1st ~ 18K Patients, Probably will Start with 6-8K then Ramping Up similar to $FMS
1 · Reply
Noname2022
Noname2022 May. 27 at 3:37 AM
$CRMD $DVA $FMS $AKBA June / July ESRD update still on track!
1 · Reply
Noname2022
Noname2022 May. 27 at 2:53 AM
$CRMD $DVA “Broadly, two most common causes of hospitalization in people with kidney failure are cardiovascular disease and infection” https://usrds-adr.niddk.nih.gov/2025/end-stage-renal-disease/5-hospitalization?utm_source=chatgpt.com
0 · Reply
Noname2022
Noname2022 May. 27 at 2:36 AM
1 · Reply
Noname2022
Noname2022 May. 26 at 8:38 PM
$CRMD $DVA $FMS Medicare Advantage update: tri-party discussions https://stockanalysis.com/stocks/crmd/transcripts/673503-rbc-capital-markets-global-healthcare-conference-2026/
0 · Reply
Noname2022
Noname2022 May. 24 at 7:44 PM
$CRMD $AKBA $DVA $FMS For those following lobbying efforts…
2 · Reply
Noname2022
Noname2022 May. 23 at 9:32 PM
$AKBA $CRMD $DVA $FMS For those following polict / advocacy…
2 · Reply
Noname2022
Noname2022 May. 22 at 2:51 PM
$CRMD $DVA $FMS $AKBA Kidney lobbying Continues…
0 · Reply
Noname2022
Noname2022 May. 21 at 4:36 AM
$DVA $AKBA $CRMD Interesting DaVita breadcrumb: a recent Operations Innovation role was focused on “pharma strategy,” using clinical + financial data to identify and quantify opportunities. http://www.metrodenverjobs.com/job/detail/86813415/Sr-Data-Analyst-Operations-Innovation
2 · Reply
Noname2022
Noname2022 May. 20 at 10:58 PM
$CRMD $FMS $DVA I think FMS CEO is referring to these 3 way MA discussions mentioned by Joe about Defencath, top 5 MA plans, and current 3 DO’s utilizing
0 · Reply
Noname2022
Noname2022 May. 20 at 9:02 PM
$AKBA $DVA $FMS $CRMD https://www.kidney.org/press-room/home-dialysis-bill-signals-progress-treatment-access
1 · Reply
Noname2022
Noname2022 May. 20 at 6:24 PM
$FMS $DVA $CRMD https://www.kff.org/medicare/medicare-advantage-enrollment-update-and-key-trends/
0 · Reply
Noname2022
Noname2022 May. 20 at 5:58 PM
$DVA $CRMD Re: Defencath & Davita
2 · Reply
Noname2022
Noname2022 May. 20 at 5:53 PM
$CRMD $DVA $FMS Joe commentary on Top 5 MA’s with DO’s Sounds like a beautiful three way conversation
1 · Reply
Noname2022
Noname2022 May. 20 at 4:01 PM
$AKBA $DVA $FMS $CRMD Regarding CMS / K-CAPA RBC comments by Joe
2 · Reply
Noname2022
Noname2022 May. 16 at 11:33 PM
6 · Reply
Noname2022
Noname2022 May. 15 at 4:12 PM
1 · Reply